Nothing said here yet.
to join the conversation.
| Cowan ElviaSVP, Finance & CAO | Sell | 19,000 | $1.6M | Mon, Oct 5 |
| Wassil JimEVP, Chief Scientific Ofc, COO | Sell | 18,000 | $1.6M | Mon, Oct 5 |
| Wassil JimEVP, Chief Scientific Ofc, COO | Sell | 2,155 | $122.1K | Thu, Oct 1 |
| Wassil JimEVP, Chief Scientific Ofc, COO | Sell | 95 | $5.4K | Thu, Oct 1 |
| Wassil JimEVP, Chief Scientific Ofc, COO | Sell | 1,334 | $79.4K | Wed, Sep 9 |
| Wassil JimEVP, Chief Scientific Ofc, COO | Sell | 1,381 | $84.5K | Fri, Sep 4 |
| Wassil JimCHIEF OPERATING OFFICER | Sell | 1,537 | $93.6K | Tue, Sep 1 |
| Wassil JimCHIEF OPERATING OFFICER | Sell | 924 | $56.3K | Tue, Sep 1 |
| Wassil JimCHIEF OPERATING OFFICER | Sell | 713 | $43.8K | Tue, Sep 1 |
| Wassil JimCHIEF OPERATING OFFICER | Sell | 303 | $18.6K | Tue, Sep 1 |
| Gilbert Cisneros | Buy | $8.0K | Thu, Jul 16 | Fri, Aug 14 |
| Gilbert Cisneros | Buy | $8.0K | Wed, May 13 | Fri, Jun 5 |
| Gilbert Cisneros | Buy | $8.0K | Tue, May 12 | Fri, Jun 5 |
The mean of analysts' price targets for Vaxcyte (PCVX) points to an 87.4% upside in the stock.
The average of price targets set by Wall Street analysts indicates a potential upside of 75.6% in Vaxcyte (PCVX).
Vaxcyte (PCVX) has just raised roughly US$1b through concurrent common stock, pre funded warrant and convertible note offerings, following positive Phase 3 data for its VAX 31 pneumococcal vaccine candidate.
Biotech stocks took a hit Tuesday, with Vaxcyte, Moderna and Revolution Medicines posting some of the steepest losses.
Key TakeawaysVaxcyte shares fell 10% after the company launched a $1 billion raise, split between $500 million of stock and $500 million of convertible notes, hours after its Phase 3 win.
VAX-31 matched or beat Pfizer's Prevnar 20 and Merck's Capvaxive on nearly all measured strains in the OPUS-1 trial
Vaxcyte (NASDAQ:PCVX) said its investigational 31-valent pneumococcal conjugate vaccine, VAX-31, met all pre-specified primary immunogenicity endpoints in the pivotal Phase III OPUS-1 trial in adults.
Vaxcyte said earlier on Monday that its experimental pneumonia vaccine, VAX-31, met the main goals of a late-stage study in adults 50 and older.